This summary is generated by an algorithm. If you find any mistakes, let us know.

Health Care Health Diagnostics North America Personal Health Therapeutics

Xealth Secures $24 Million in Series B Funding to Accelerate Digital Health

– Xealth, the leader in enabling digital health at scale, announced that the company has secured $24 million in Series B funding led by Advocate Aurora Enterprises, a subsidiary of Advocate Aurora Health.
– Seven additional health systems – Banner Health, ChristianaCare, Cone Health, Memorial Hermann, Nebraska Medicine, Novant Health and Stanford Health Care – join existing health system investors Atrium Health, Cleveland Clinic, Froedtert & MCW Health Network, MemorialCare Innovation Fund, Providence and UPMC.
– This brings the company’s total funding to date to $52.6 million.
– Use of digital therapeutics and remote patient monitoring is accelerating as they help fill a necessary role in extending care options for patients.

Source
Health Care Health Diagnostics Health Insurance Southeast Asia

Indonesia-based Rey Assurance launches its holistic approach to insurance with $1M in funding

– Rey Assurance, an Indonesian insurtech startup, raised $1m in pre-seed funding.
– The round was led by Trans-Pacific Technology Fund (TPTF).
– TPTF managing partner Glenn Kline said that Rey’s founding team was “really the driver” for its investment.
– Rey was founded this year by Evan Tanotogono, former head of digital channel at Sequis, one of Indonesia largest insurers, and Bobby Siagian, who held lead engineering roles at companies including Tokopedia and Sea Group.
– They created Rey to address the low penetration of life and health insurance in Indonesia.

Source
Health Care Health Diagnostics Medical Device North America

Nectero Medical Completes $19.5 Million Series C Financing

Nectero Medical Inc. announced the closing of its $19.5m Series C financing round.
Proceeds will support the companys in vivo and clinical trials to develop a potentially disruptive treatment platform that stabilizes smallto midsized aortic aneurysms by significantly reducing their growth rate.

Source
Biotechnology Genetics Health Diagnostics Life Science North America

Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics

– Mammoth Biosciences has secured $195m in financing, joining the select ranks of “unicorn” startups with a valuation of more than $1bn.
– The funds will enable the company to broaden its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics.
– Mammoth’s CRISPR platform leverages the largest toolbox of novel Cas enzymes, driven by its proprietary protein discovery engine which leverages the natural diversity of life.

Source
Biotechnology Health Care Health Diagnostics Medical Device North America

Seattle startup RareCyte raises $24M to advance new high-speed cell imaging platform

– Seattle-based startup RareCyte announced $24m in new funding.
– The funding will fuel the commercialization and development of its new Orion cell imaging and analysis platform, launched last year.
– The company markets kits for preparing samples from blood or tissues and instruments to optically measure cells.
– Their products aim for automation and high-volume of sampling.

Source
Health Care Health Diagnostics Medical North America Therapeutics

Blue Note Therapeutics Raises $5.2M in Additional Series A Funding

– Blue Note Therapeutics raised an additional $5.2m in Series A financing, bringing the company’s Series A financing to a total of $31m.
– The financing was provided by Memorial Sloan Kettering Cancer Center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC.
– The additional proceeds will strengthen Blue Note’s capacity to develop evidence-based therapeutics that serve an increasing number of cancer patients.

Source
Biotechnology Health Care Health Diagnostics North America

YourBio Health Raises $21M in Funding

– YourBio Health from Boston develops a personal health information company, raised $21M in funding.
– Series A round was led by Flagship Pioneering with participation from Newpath Partners.
– The company intends to use the funds to accelerate growth and support forthcoming product launches.

Source
Biotechnology Genetics Health Diagnostics North America Pharmaceutical

bluebird bio Secures $75 Million in Private Placement Equity Financing

– bluebird bio, Inc. announced that it has entered into an agreement for a $75m private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process.
– Proceeds from the financing will support ongoing R&D and commercialization investments for bluebird bio and for 2seventy bio, which plan to launch as independent companies in October 2021.
– bluebird plans to complete the spin-off of 2seventy in October 2021, subject to customary conditions, including effectiveness of the Form 10, a favorable opinion from the IRS with respect to the tax-free nature of the transaction, and final approval from bluebird’s Board of Directors.

Source
Emergency Medicine Health Care Health Diagnostics Medical Device Western Europe

Owlstone Medical Raises $58M in Funding

– Owlstone Medical is a Cambridge UK-based global leader in Breath Biopsy® for applications in early disease detection and precision medicine.
– Company raised $58m in funding.
– The round was led by Horizons Ventures, which now takes a seat on Owlstone Medical’s Board, and is joined by other existing and high-profile new investors from Asia, the Middle East and the United States.
– The new investment will be used to accelerate the company’s commercialization of its Breath Biopsy tests.

Source
Artificial Intelligence Big Data Health Care Health Diagnostics Machine Learning Medical Medical Device Software Software Engineering Western Europe

contextflow Raises €6.7M in Series A Funding

– contextflow from Vienna develops artificial intelligence for medical image analysis.
– A second closing included an additional €2M from new co-investor Peak Pride Management GmbH, HPH (Hans Peter Haselsteiner) Start-up Unit and current investor APEX Ventures with its “APEX Best in Class” fund. A first closing was led by B&C Innovation Investments GmbH (BCII) and included participation from new co-investor TTIP Beteiligungs GmbH and current investors APEX Ventures, Crista Galli Ventures, IST cube, Nina Capital and Novacapital.
– The new investment will be used to accelerate market entry in Europe and the US, including obtaining FDA clearance for contextflow SEARCH Lung CT, as well as extending its offerings to include new products and features covering a wider range of organs and modalities.

Source
Apps Health Care Health Diagnostics Internet Mobile Apps North America Personal Health

Solv Raises $45M in Series C Funding

– Solv is a San Francisco CA-based network of same-day and next-day healthcare providers.
– The company raised $45M in Series C funding.
– The round was led by Acrew Capital and Corner Ventures with participation from Greylock Partners and Benchmark Capital.
– The new funding will be used to expand the company’s national network of healthcare providers, consumer driven healthcare offerings like same-day in person appointments and virtual care, and increased cost transparency for patients.

Source
Health Care Health Diagnostics Western Europe

DnaNudge Raises $60M in Series A Funding

– DnaNudge is a London UK-based company focused on genetics testing and medical diagnostics.
– The company raised $60M in Series A funding.
– The round was led by Ventura Capital with participation from Bank Julius Baer.
– The new investment will be used to accelerate the deployment of its rapid genetic testing solutions, including the sample-to-result RT-PCR COVID-19 test (‘CovidNudge’), which is in use in healthcare settings around the world.

Source
Biotechnology Health Care Health Diagnostics North America Pharmaceutical

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

– Neurogastrx, a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced the successful completion of a $60m Series B crossover round led by Vivo Capital.
– Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors.
– Proceeds from the financing will be used to advance the company’s pipeline of GI therapies for serious conditions that impact millions of people yet are not effectively treated.

Source
Health Care Health Diagnostics Medical Medical Device North America

Trice Medical Raises Series D Led by Bioventus

– Trice Medical, a Malvern, PA-based imaging technology company, raised a Series D funding.
– The amount of the deal was not disclosed.
– The funding was led by Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing.
– In conjunction with leading the funding, Bioventus will receive exclusive sales and distribution rights to Trice’s products outside of the US.

Source
Artificial Intelligence Health Diagnostics Medical Device North America

Zilia Raises $4M in Seed Funding

– Zilia is a Quebec, Canada-based ocular health startup.
– Company raised $4m in seed funding.
– The round was led by Anges Québec, with participation from the Government of Quebec through its new program, Impulsion PME, administered by Investissement Québec as a government agent, and other backers.
– The new investment will be used to complete the regulatory approval process for the clinical launch of Zilia Ocular, its first product.

Source
Eastern Asia Health Care Health Diagnostics

Speclipse Raises $7.7M in Funding

– Speclipse is a Seoul, South Korea-based developer of laser spectroscopic and AI-based medical diagnosis technologies.
– The company raised $7.7m in funding.
– The round was led by Signite Partners with participation from BNH Investment, Shinhan Capital, MiCo and MiCoBioMed.
– The new investment will be used to accelerate growth, expand operations and its business reach.

Source
Family Health Care Health Diagnostics North America Women's

Maven Clinic Raises $110M in Series D Funding

– Maven Clinic from New York provides virtual clinic for women’s and family health, offering continuous, holistic care for fertility, pregnancy and parenting.
– Company raised $110m in Series D funding.
– The round was led by Dragoneer Investment Group, Lux Capital with participation from BOND, Sequoia, Oak HC/FT, and Icon Ventures, as well as Oprah Winfrey.
– The new investment will be used to expand into new populations and to invest in additional product innovation to further enhance its member experience designed to improve clinical outcomes.

Source
Artificial Intelligence Computer Vision Health Care Health Diagnostics Medical Software Western Europe

Ultromics Raises $33M in Series B Funding

– Ultromics, an Oxford, UK-based company focused on advancing AI enabled cardiovascular imaging solutions, raised $33M in series B funding.
– The round was led by Blue Venture Fund with participation from Optum Ventures, GV and Oxford Sciences Innovation.
– The new investment will be aimed at accelerating the use of AI-enabled echocardiograms to improve patient care, and bring improved diagnostic quality and resource savings to hospitals.

Source
Biotechnology Health Care Health Diagnostics Medical Device North America

Encellin Closes $5.9M Seed Financing Co-Led by Khosla Ventures and SV Latam Capital

– Encellin closed a $5.9M Seed financing round.
– The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator.
– The new funding will be used to advance development of its technology platform and programs in hypoglycemia and hypocalcemia.
– Encellin will also expand into areas with readily available renewable cell sources and engineered cells, to encapsulate any cellular cargo in products from its proprietary platform.
– Encellin builds implantable “cell pouches” to treat chronic diseases.
– The company’s technology combines ad novel cell encapsulation technology with functional cell therapies to treat chronic diseases, starting with endocrine disorders.

Source
Computer Vision Health Care Health Diagnostics Medical North America

Iterative Scopes Raises $30 Million Series A Financing to Advance AI-Driven Precision Medicine for Gastroenterology

– Iterative Scopes closed a $30m Series A financing.
– The round was led by new investor Obvious Ventures, with participation from Eli Lilly, Johnson & Johnson Innovation, the venture capital firms Breyer Capital and Seae Ventures, as well as a number of leaders in healthcare, including Lee Shapiro, Zach Weinberg and Nat Turner.
– The funds will be used to further develop the company’s core algorithmic innovations and to advance its growing life sciences businesses.
– The company is building a powerful set of proprietary artificial intelligence (AI)-driven computational tools to identify appropriate treatments and guide clinical trials for patients suffering from gastrointestinal diseases.

Source
Eastern Asia Health Diagnostics Manufacturing Medical Device

Scivita Medical Technology Receives RMB0.4 Billion in Series B Financing

– Scivita Medical Technology Co., Ltd. from Hong Kong is a maker of endoscopy products.
– The company received nearly RMB0.4 Billion in Series B financing.
– Backers included new investors such as Hudson Bay Capital Management and Prime Capital, as well as existing shareholders such as GL Ventures, Lilly Asia Ventures and Matrix Partners China.
– The new investment will be used for research and development, capacity expansion, and domestic and international commercialization of innovative products in endoscopy and related fields.

Source
Biotechnology Genetics Health Care Health Diagnostics Medical Device North America

Strata Oncology Closes $90M Series C Financing

– Strata Oncology, Inc. from Ann Arbor develops a comprehensive genomic profiling platform to deliver a portfolio of treatment selection tests for solid tumors.
– Series C $90m financing was led by Wellington Management and joined by other new investors.
– The new investment will be used to accelerate the company’s pipeline of novel RNA-based treatment selection tests for solid tumors.

Source
Artificial Intelligence Diabetes Health Care Health Diagnostics Hospital Medical Medical Device North America Personal Health Pharmaceutical

Eyenuk Raises $6.2M in Funding

– Eyenuk, a Los Angeles CA-based artificial intelligence (AI) medical technology and services company, raised $6.2M in funding.
– The round was led by AXA IM, through AXA IM Alts.
– The company intends to use the funds to accelerate commercialization of the EyeArt® AI System.

Source
Biotechnology Genetics Health Care Health Diagnostics Medical North America

BillionToOne Closes $55M Series B Funding

– BillionToOne, Inc. from Menlo Park develops molecular diagnostics company.
– The company closed a $55m Series B funding round.
– The round was led by existing investor Hummingbird Ventures and incoming investor Four Rivers Group with participation from Neotribe Ventures, Norwest Venture Partners, Y Combinator, and Libertus Capital.
– The new investment will be used to expand the company’s clinical lab and commercial team nationwide.

Source
Biotechnology Health Care Health Diagnostics Life Science North America Pharmaceutical

Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology

– Xilis, Inc. announced the close of a $70m Series A financing.
– The round was led by Mubadala Capital and joined by new investors including GV, LSP, Catalio Capital Management, and Duke Angel Network.
– Current investors Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures, and Alix Ventures also participated.
– Xilis is based on decades of biomedical, oncology, and stem cell research by its three co-founders.
– Dr. Clevers, a Breakthrough Prize winner, is the inventor and pioneer of the organoid technology.
– Dr. Shen and Dr. Hsu are accomplished engineering and medical professors at Duke University and experts in precision medicine.

Source
Health Care Health Diagnostics Southeast Asia

ObvioHealth Raises $31M in Funding

– ObvioHealth is a NYC-based global Virtual Research Organization (VRO).
– The company raised $31m in funding.
– The round was led by new investors Dedalus Group, an international healthcare IT and diagnostic software provider, and Novotech Health Holdings Pte. Ltd., Asia Pacific’s biotech-specialist CRO.
– The company intends to use the funds to boost the IT capabilities of its proprietary ecosystem and platform for conducting virtual clinical trials, including the GDPR compliant bridging software to query EHR data, and make key hires in the coming year, particularly in Asia, with plans to expand the Singapore office into a technology hub.

Source
Health Care Health Diagnostics North America

Adela Raises $60M in Series A Funding

– Adela specializes in detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.
– The company raised $60M in Series A funding.
– The round was led by F-Prime Capital with participation from OrbiMed, Deerfield Management, Decheng Capital and RA Capital Management.
– The company plans to use the advance its technology towards commercialization, with initial applications across the cancer care continuum from early detection to disease monitoring.

Source
Biotechnology Health Diagnostics Medical Device Western Europe

Leukocare Raises USD 17.5M in Financing

– Leukocare AG, a Martinsried/Munich, Germany and Milford, MA, USA-based biotechnology company specialized in the field of biopharmaceutical formulation development, closed a USD 17.5m (€14.6m) financing.
– The round was led by Petrichor Healthcare Capital Management with participation from existing shareholders.
– Proceeds will be used to accelerate Leukocare’s US expansion activities, bolster the company’s expertise in the fields of viral vector and vaccine formulation, as well as the emerging field of mRNA formulation, and to expand its suite of bioinformatics capabilities.

Source
Health Care Health Diagnostics Medical Medical Device North America Software

EvoEndo Raises $10.1M in Funding

– EvoEndo, Inc. is a Denver CO-based preclinical medical device company which specializes in developing systems for unsedated Transnasal Endoscopy (TNE).
– The company raised $10.1M in funding.
– The Backers were undisclosed.
– The company intends to use the funds to advance its technology.

Source
Health Care Health Diagnostics Medical mHealth North America

LetsGetChecked Announces $150 Million Series D Fundraise to Grow Comprehensive Virtual Care Capabilities

– LetsGetChecked announced the completion of a $150m Series D round of financing.
– The funding was led by Casdin Capital with continued participation from CommonFund Capital, Illumina Ventures, Optum Ventures, Transformation Capital, HLM Venture Partners, Qiming Venture Partners USA, and professional golfer Rory Mcllroy through Symphony Ventures, an investment partnership.
– This latest financing brings the total capital raised by LetsGetChecked to more than $260m.
– LetsGetChecked will use the new capital to launch care pathways, a 360-degree customer care journey that will provide remote care for patients with ailments and chronic conditions.
– Care pathways is enabled by LetsGetChecked’s core offerings, including telehealth services, pharmacy capabilities, and at-home diagnostics.

Source
Health Care Health Diagnostics Medical Medical Device North America Software

EvoEndo® Raises $10.1 Million to Make Unsedated Transnasal Endoscopy a Reality for Patients and Physicians

– EvoEndo secured $10.1M in equity financing.
– The funding round included a variety of family offices and early-stage life science investors.
– The funding will be used to further EvoEndo’s innovative technology designed to help physicians diagnose, treat, and monitor conditions for a variety of gastrointestinal disorders.

Source
Biotechnology Health Care Health Diagnostics North America

entrinsic bioscience Secures $49 million in Financing to Accelerate Development and Commercialization of Next Generation Functional Ingredients and Active Pharmaceutical Ingredients

– Jefferies acted as sole lender to EBS. Aon Plc, using its proprietary intellectual property (IP) valuation platform to value EBS’ IP portfolio, arranged for an IP Collateral Insurance policy for Jefferies, collateralized by EBS’ IP portfolio.
– EBS is raising $49m in non-dilutive growth capital from Jefferies Group LLC’s subsidiary, Jefferies Funding LLC (Jefferies).
– Following Series A and B raises, including multiple rounds of investment from Johnson & Johnson INNOVATION | JJDC.
– EBS is a leader in functional ingredients and bioactives.

Source
Health Care Health Diagnostics North America Personal Health

Norbert Health Closes $5M Seed II Funding

– Norbert Health is a Brooklyn, NY-based contactless, multi-modal vital sign scanning company.
– The company closed a $5M seed II funding round.
– The round was co-led by Serena.vc and HCVC with participation from Exor, C4 Ventures, LDV and Newlab.
– The new investment will be used to grow the team, build additional features, pursue medical certification, and expand operations.

Source
Cloud Data Services Genetics Health Care Health Diagnostics North America Personal Health

Genoox Raises $8M in Funding

– Genoox is a Palo Alto in CA-based driven genomic data platform provider.
– The company raised $8m in funding.
– The round was led by IN Venture, a Sumitomo Corporation backed venture fund, with participation from Infinity Medical and existing investors Inimiti, Glilot Capital and Triventures.
– The new funding will be used to expand its community of genetic professional users and enhance the network effect created by sharing genetic insights on its platform.

Source
Biotechnology Genetics Health Diagnostics Information Technology Medical North America

Electronic Sequencing Platform GenapSys Raises $70 Million

– GenapSys is a company developing a highly accurate and scalable electronic sequencing platform.
– The company raised $70m in Series D equity financing.
– The investors in the round included Farallon Capital Management, L.L.C., Soleus Capital, an affiliate of PBM Capital, and additional new investors.
– The proceeds from this financing will be used to continue advancing GenapSys’ semiconductor based next-generation sequencing (NGS) platform.

Source
Biotechnology Health Care Health Diagnostics Southeast Asia

Esco Lifesciences Closes a Record-Setting US$200M Series A Round Led by Vivo Capital and Novo Holdings

– Esco Lifesciences announced the close of an over-subscribed US$200m Series A and Crossover round.
– The financing was led by Vivo Capital and Novo Holdings A/S, with participation from new investors including China Investment Corporation, Singapore-based global investor EDBI, a reputable, long-term institutional investor, and other sophisticated investors.
– Esco Lifesciences, a leading provider of life sciences tools and services, is poised to benefit from the sustained growth of the healthcare and biopharma industries in Asia and globally.

Source
Biotechnology Health Care Health Diagnostics Medical North America

HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital

– HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m.
– The company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE: HTGC).
– The Series B round included new investors Huizenga Capital Management, Monashee Investment Management, funds managed by Tekla Capital Management LLC, Hercules Capital, Mount Sinai Innovation Partners and other undisclosed investors.
– Returning investors, including ARCH Venture Partners, Magnetic Ventures, Bristol Myers Squibb, Trinitas Capital, and others from the Series A syndicate also participated in the round.

Source
Biopharma Biotechnology Health Diagnostics Life Science Medical Therapeutics Western Europe

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

– Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.
– The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.

Source
Health Care Health Diagnostics Hospital mHealth North America Psychology

Eleanor Health Announces $20M Series B

– Eleanor Health, an outpatient addiction and mental health provider, has closed an oversubscribed $20M Series B financing.
– The company received participation from all existing investors including Town Hall Ventures, Echo Health Ventures, and Mosaic Health Solutions, as well as new participation from Warburg Pincus.

Source
Biotechnology Health Diagnostics Life Science North America

KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors

– KIYATEC, Inc secured a $2.5m investment from Seae Ventures.
– The investment comes on the heels of other recent announcements of success for KIYATEC.
– The company’s platform has been shown to be clinically predictive for patient-specific response to chemotherapy and targeted agents, and it has been analytically validated in both ovarian cancer and high-grade gliomas.
– KIYATEC has the potential to significantly improve outcomes for patients and their providers, not just for one cancer type, but across many solid tumors.

Source
Biotechnology Health Care Health Diagnostics Medical Device North America

Ceribell Raises $53M in Series C Financing

– Ceribell, Inc. from Mountain View, CA develops a non-invasive brain monitor to detect seizure in patients.
– The company closed a $53m Series C round.
– The round was co-led by Longitude Capital and The Rise Fund with participation from new investors RA Capital Management, Redmile Group and Red Tree Venture Capital, with existing shareholders.
– The funding will be used to further expand the company’s commercial presence in emergency departments and intensive care units globally.

Source
Genetics Health Care Health Diagnostics North America Therapeutics Wellness

C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B

– C2i Genomics, a cancer detection company, raised $100m in Series B funding.
– The round was led by Casdin Capital and joined by new investors including New Enterprise Associates (NEA), and existing investors including Sequoia Capital, and others.
– The company plans to use the funding to expand its research and development efforts.

Source
Genetics Health Care Health Diagnostics North America Therapeutics Wellness

C2i Genomics Raises $100M in Funding

– C2i Genomics from New York, NY provides a cloud-based cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease.
– The company raised $100m in financing.
– The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others.
– The new investment will be used to accelerate the company’s clinical development and commercialization of its C2-Intelligence Platform.

Health Care Health Diagnostics North America Personal Health

Allergy Amulet Closes Additional Seed Funding

– Allergy Amulet has announced additional Seed funding, bringing its total amount raised in the round to $4.1m.
– The Seed extension includes investments from AllerFund, the first venture capital firm dedicated to driving social impact for those managing food allergies.
Lightship Capital also participated.

Source
Health Care Health Diagnostics Hospital North America

Crossover Health Secures $168 Million in Series D Financing to Fuel Expansion of National Primary Health Service

– Crossover Health has secured $168m in Series D financing led by Deerfield Management Company.
– The capital will be applied to continuing the national expansion of Crossover’s Connected System of Health for employers and payers.
– Crossover Health is a relationship-based, tech-enabled, national healthcare organization that integrates both virtual and in-person care for employers and health plans.
– Goldman Sachs & Co. LLC acted as the exclusive placement agent for the financing and Latham & Watkins LLP served as legal counsel to Crossover Health.

Source
Alternative Medicine Artificial Intelligence Biotechnology Health Care Health Diagnostics North America

Scipher Medicine Raises $82M in Series C Funding

– Scipher Medicine completed an $82m Series C funding.
– The round was led by aMoon and Northpond Ventures, with participation from Echo Health Ventures and existing investors, Khosla Ventures and Alumni Ventures.
– The new funding will be used to expand commercial efforts for its patient molecular signature test, PrismRA.

Source
Biotechnology Health Diagnostics Life Science North America

CND Life Sciences Closes $2.4M Seed Financing

– CND Life Sciences, Inc. is a Phoenix-based innovative medical technology company.
– The company closed a $2.4m seed financing round.
– HonorHealth, a local health system serving 1.6 million people in the greater Phoenix area, joined several experienced financial investors in funding the round.
– The company intends to use the funds to expand laboratory operations and accelerate sales and marketing initiatives for its Syn-One TestTM, an evidence-based tool that aids the diagnosis of serious neurological disorders including Parkinson’s disease and dementia with Lewy bodies.

Source
Fitness Health Care Health Diagnostics Hospital North America Wellness

Ro Raises $500 Million in Series D Funding to Expand its Vertically Integrated Primary Care Platform

– Ro Raises $500 Million in Series D Funding to Expand its Vertically Integrated Primary Care Platform
– Ro is the healthcare technology company
– The company has completed a $500 million Series D fundraising round led by existing investors General Catalyst, FirstMark Capital and TQ Ventures, with significant participation from existing investors SignalFire, Torch Capital and BoxGroup as well as new investors Altimeter Capital, Baupost Group, Dragoneer Investment Group, ShawSpring Partners, Radcliff, and 776.
– The Series D brings Ro’s total fundraising since its founding in 2017 to $876 million.
– Ro will use the newly-raised capital to strengthen its vertically integrated primary care platform.

Source
Biotechnology Health Diagnostics Medical North America

Biodesix Announces Closing of New $30 Million Term Loan

– Biodesix, Inc. (NASDAQ: BDSX; “Biodesix” or the “Company”) a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that it has closed on a new $30 million term loan (New Term Loan) which matures on March 1, 2026.
– The proceeds were used to repay outstanding borrowings of $25.9 million under the Company’s existing term loan with Innovatus Life Sciences Lending Fund I, LP (Innovatus), which was terminated upon payment, and the remaining proceeds of approximately $4 million will enhance existing liquidity for general corporate purposes.

Source
Big Data Bioinformatics Biotechnology Health Care Health Diagnostics North America

Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics

– Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102m Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio.
D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures.
– Sepsis caused more than five million deaths annually worldwide before the COVID-19 pandemic, and severe COVID-19 has been recognized as viral sepsis. In addition, antibiotic resistance is directly responsible for more than 700,000 deaths annually worldwide.

Source
Health Diagnostics Information Services Medical Device North America Wearables

Know Labs Announces Close of Financing

– Know Labs closed on $14.2m of financing.
– The financing was led by existing investors and insiders.
– The financing will support continuing development and clinical testing on its platform technology with its first focus on non-invasive blood glucose monitoring, and future FDA approval.
– The current financing provides sufficient capital so that management can ensure product development stays on track and an up list to a major exchange is event driven rather than driven by a need for capital.

Source
Biotechnology Genetics Health Care Health Diagnostics Information Technology Life Science North America Personal Health

Variantyx Secures $20M in Series C Funding

– Variantyx, a Boston, MA-based hereditary disease testing company, secured $20M in Series C funding.
– The round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners.
– In conjunction with the funding, Zafrira Avnur, PhD, Quark Venture Chief Scientific Officer & Partner, will join the Variantyx board of directors.
– The company intends to use the funds for development of its tumor diagnostic solutions and the expansion of sales.

Source
Biotechnology Health Care Health Diagnostics Medical North America

Ault Global Holdings Announces $10 Million Investment in Alzamend Neuro

– Ault Global Holdings, Inc. (NYSE American: DPW), a diversified holding company, announced today that its wholly owned subsidiary, Digital Power Lending, LLC, has entered into a securities purchase agreement with Alzamend Neuro, Inc. to invest $10m in Alzamend common stock and warrants.
– Alzamend Neuro, Inc. is an early stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders.
– Alzamend currently has two product candidates, aiming to bring treatments or cures for Alzheimer’s disease and other neurodegenerative diseases and psychiatric disorders to market at a reasonable cost as quickly as possible.

Source
Artificial Intelligence Biopharma Health Care Health Diagnostics North America Software

Paige Secures Financing from KKR for Total Series C Funding Round of Over $125 Million

– Paige, a global leader in AI-based diagnostic software in pathology, today announced that KKR, a leading global investment firm, joined Casdin Capital and Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as co-leads in its Series C financing round, bringing the round to over $125 million.
– Paige will use this new capital to expand its geographic footprint as it accelerates the development of AI-based clinical applications, biomarkers and diagnostics.
– Additional investors in the Series C round include Catalio Capital Management, existing investors and other funds, as previously announced.
– For KKR, the investment is being funded through the firm’s Health Care Strategic Growth Fund, which is focused on investing in high-growth health care-related companies for which KKR can be a unique partner in helping reach scale.

Source
Analytics Artificial Intelligence Asia Health Diagnostics Machine Learning

Ibex raises $38M for AI that diagnoses diseases

– Ibex Medical Analytics, a Tel Aviv, Israel-based startup developing a product suite for clinical decision-making and pathology laboratory workflows, today announced that it raised $38 million in funding.
– The global big data analytics market for health care was valued at $16.87 billion in 2017 and is projected to reach $67.82 billion by 2025, according to a recent report from Allied Market Research. It’s believed that health care organizations’ implementation of big data analytics might reduce annual costs by over 25% in the coming years. Better diagnosis and disease predictions, assisted by AI and analytics, can lead to cost reduction by decreasing hospital readmission rates, among other factors.

Source
Analytics Artificial Intelligence Asia Health Diagnostics Machine Learning

Ibex Medical Analytics Raises $38 Million to Accelerate Adoption of AI-powered Cancer Diagnostics in Pathology

– Ibex Medical Analytics announced a $38m Series B financing round led by Octopus Ventures and 83North, with additional participation from aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital, the corporate venture arm of Dell Technologies.
– Ibex transforms cancer diagnosis by harnessing unique artificial intelligence (AI) and machine learning technology at an unprecedented scale.
– The company’s Galen™ platform supports physicians and providers to improve diagnostic accuracy and efficiency, and enables development of new AI tools for precision medicine in oncology.
– Pathologists play a crucial role in the detection and diagnosis of disease, with their assessment being vital for correct treatment decisions in cancer care.
– However, a rise in cancer prevalence and advances in personalized medicine have resulted in growing diagnostic complexity that significantly increases pathologists’ workloads.

Source
Health Care Health Diagnostics Hospital Medical Device North America

With $19M A round, Halo Dx combines data streams to better diagnose cancers, dementia and more

– Halo Diagnostics, a healthcare startup, raised $19m in Series A funding.
– The round was led by Khosla Ventures and joined by Founders Fund, and others.
– The company plans to use the funding to expand its facilities and services.

Source
Apps Consumer Health Care Health Diagnostics Medical Device mHealth North America

TytoCare Raises Additional $50M in Extended Series D Funding

– TytoCare is a NYC-based healthcare industry’s modular device and telehealth platform for AI-powered, on-demand remote medical examinations.
– The company raised $50M in a Series D extension round.
– The extension round was led by Insight Partners with participation from new growth investors Tiger Global Management and Qumra Capital and existing investors Qualcomm Ventures LLC, Olive Tree Ventures, and Shenzhen Capital Group Company.

Source
1 2
Crunchbase icon

Content report

The following text will be sent to our editors: